IL144351A - A combination of formoterol and momatasone furoat for the treatment of asthma - Google Patents

A combination of formoterol and momatasone furoat for the treatment of asthma

Info

Publication number: IL144351A
Authority: IL; Israel
Prior art keywords: medicament according; medicament; formoterol; dry powder; dispersion
Prior art date: 1999-03-03

Application number

IL14435100A

Other languages

English (en)

Hebrew (he)

Other versions

IL144351A0 (en

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-03

Filing date

2000-03-01

Publication date

2005-12-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10848904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144351(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-01 Application filed by Novartis Ag filed Critical Novartis Ag

2002-05-23 Publication of IL144351A0 publication Critical patent/IL144351A0/xx

2005-12-18 Publication of IL144351A publication Critical patent/IL144351A/en

Links

WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 title claims abstract description 25
238000011282 treatment Methods 0.000 title claims abstract description 24
208000006673 asthma Diseases 0.000 title description 16
229940021608 formoterol and mometasone Drugs 0.000 title description 5
239000003814 drug Substances 0.000 claims abstract description 42
230000002757 inflammatory effect Effects 0.000 claims abstract description 22
229960002744 mometasone furoate Drugs 0.000 claims abstract description 20
208000027771 Obstructive airways disease Diseases 0.000 claims abstract description 19
208000027866 inflammatory disease Diseases 0.000 claims abstract description 17
229960002848 formoterol Drugs 0.000 claims abstract description 16
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 11
239000012453 solvate Substances 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims description 37
239000000843 powder Substances 0.000 claims description 36
239000000443 aerosol Substances 0.000 claims description 23
RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims description 17
239000006185 dispersion Substances 0.000 claims description 17
239000003380 propellant Substances 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 15
229960003610 formoterol fumarate dihydrate Drugs 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 12
238000002648 combination therapy Methods 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 8
229930195733 hydrocarbon Natural products 0.000 claims description 5
150000002430 hydrocarbons Chemical class 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 claims 1
239000004480 active ingredient Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
239000006199 nebulizer Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
-1 2-furanylcarbonyl Chemical group 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
229960000193 formoterol fumarate Drugs 0.000 description 4
229940071648 metered dose inhaler Drugs 0.000 description 4
230000000414 obstructive effect Effects 0.000 description 4
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229960001021 lactose monohydrate Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
YJRJVBRVTVDQQT-XTEKXEGTSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol trihydrate Chemical compound O.O.O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O YJRJVBRVTVDQQT-XTEKXEGTSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000035874 hyperreactivity Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
230000004199 lung function Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
206010035653 pneumoconiosis Diseases 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
LFKMOLWAKAJMHB-LFPSBFENSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O LFKMOLWAKAJMHB-LFPSBFENSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
208000007596 Byssinosis Diseases 0.000 description 1
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
206010069351 acute lung injury Diseases 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
235000013844 butane Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
125000001995 cyclobutyl group Chemical class [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
150000001942 cyclopropanes Chemical class 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000013849 propane Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
229960000257 tiotropium bromide Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IL14435100A 1999-03-03 2000-03-01 A combination of formoterol and momatasone furoat for the treatment of asthma IL144351A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9904919.9A GB9904919D0 (en)	1999-03-03	1999-03-03	Organic compounds
PCT/EP2000/001722 WO2000051591A1 (en)	1999-03-03	2000-03-01	Combinations of formoterol and mometasone furoate for asthma

Publications (2)

Publication Number	Publication Date
IL144351A0 IL144351A0 (en)	2002-05-23
IL144351A true IL144351A (en)	2005-12-18

Family

ID=10848904

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14435100A IL144351A (en)	1999-03-03	2000-03-01	A combination of formoterol and momatasone furoat for the treatment of asthma

Country Status (27)

Country	Link
US (4)	US20020055494A1 (de)
EP (2)	EP1156790B1 (de)
JP (3)	JP2002538110A (de)
KR (1)	KR100682418B1 (de)
CN (1)	CN1196478C (de)
AT (1)	ATE241970T1 (de)
AU (1)	AU770739B2 (de)
BR (1)	BR0008699A (de)
CA (1)	CA2362499C (de)
CL (1)	CL2004001170A1 (de)
CZ (1)	CZ294089B6 (de)
DE (1)	DE60003160T2 (de)
DK (1)	DK1156790T3 (de)
ES (1)	ES2200837T3 (de)
GB (1)	GB9904919D0 (de)
HK (1)	HK1043048B (de)
HU (1)	HU229073B1 (de)
ID (1)	ID30171A (de)
IL (1)	IL144351A (de)
NO (1)	NO331428B1 (de)
NZ (1)	NZ513742A (de)
PL (1)	PL212355B1 (de)
PT (1)	PT1156790E (de)
RU (1)	RU2270670C2 (de)
SK (1)	SK286338B6 (de)
WO (1)	WO2000051591A1 (de)
ZA (1)	ZA200106442B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
GB9904919D0 (en) *	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
GB9928311D0 (en) *	1999-11-30	2000-01-26	Novartis Ag	Organic compounds
GB0009612D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Therapeutic formulations
GB0012260D0 (en)	2000-05-19	2000-07-12	Astrazeneca Ab	Novel composition
EP1311294A2 (de) *	2000-08-04	2003-05-21	Longwood Pharmaceutical Research, Inc.	Formulierung enhaltend mometason und einen brochodilatator für pulmonaren anwendung
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI324934B (en) *	2001-08-28	2010-05-21	Schering Corp	Pharmaceutical compositions for the treatment of asthma
DK3384931T3 (da) *	2002-03-01	2019-09-16	Chiesi Farm Spa	Superfin formoterolformulering
GB0207906D0 (en) *	2002-04-05	2002-05-15	3M Innovative Properties Co	Formoterol and mometasone aerosol formulations
DE60318727T2 (de) *	2002-08-27	2009-01-08	Schering Corp.	Verfahren zur herstellung von dosierinhalatorformulierungen
US20040043064A1 (en) *	2002-08-29	2004-03-04	Iorio Theodore L.	Dosage forms having reduced moisture transmission
SE527200C2 (sv) *	2003-06-19	2006-01-17	Microdrug Ag	Inhalatoranordning samt kombinerade doser av formaterol och fluticason
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US20050148563A1 (en) *	2003-09-26	2005-07-07	Schering Corporation	Pulmonary disease treatment
GB0323684D0 (en)	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
EP1684717A2 (de) *	2003-10-20	2006-08-02	Schering Corporation	Pharmazeutische aerosol-zusammensetzungen
WO2005037245A2 (en) *	2003-10-21	2005-04-28	Direct-Haler A/S	A multiple route medication for the treatment of rhinitis and asthma
EP2484382A1 (de) *	2005-03-30	2012-08-08	Schering Corporation	Medikament enthaltend einem Phosphodiesterase IV Inhibitor in einer zur Inhalation geeigneten Form
US20070099883A1 (en) *	2005-10-07	2007-05-03	Cheryl Lynn Calis	Anhydrous mometasone furoate formulation
US20080319079A1 (en) *	2005-11-23	2008-12-25	Feanny Stephen J	Method for Administering Formoterol Using a Nebulizer
US20080253970A1 (en) *	2007-02-09	2008-10-16	Schering Corporation	Stable Pharmaceutical Drug Products
US20080294720A1 (en) *	2007-05-21	2008-11-27	International Business Machines Corporation	Enhanced Online Collaboration System
US8898316B2 (en) *	2007-05-30	2014-11-25	International Business Machines Corporation	Enhanced online collaboration system for viewers of video presentations
EP3111926B1 (de)	2009-05-29	2019-12-11	Pearl Therapeutics, Inc.	Zusammensetzungen, verfahren und systeme für die respiratorische verabreichung von zwei oder mehr wirkstoffen
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918149D0 (en)	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation
WO2011093815A2 (en) *	2010-01-29	2011-08-04	Mahmut Bilgic	Pharmaceutical compositions comprising formoterol and mometasone
EP2611416B1 (de) *	2010-09-03	2015-08-19	Pharmaterials Ltd.	Pharmazeutische zubereitung zur verwendung in pulverinhalatoren
CN102416179B (zh)	2010-09-28	2014-05-07	益得生物科技股份有限公司	用于哮喘的吸入性复方组合物
GB201113662D0 (en) *	2011-08-08	2011-09-21	Prosonix Ltd	Pharmaceutical compositions
WO2014007772A2 (en) *	2012-07-05	2014-01-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Inhalation compositions comprising glucose anhydrous
US10105316B2 (en)	2012-07-05	2018-10-23	Arven llac Sanayi Ve Ticaret A.S.	Inhalation compositions comprising muscarinic receptor antagonist
RU2696582C2 (ru)	2013-03-15	2019-08-05	Перл Терапьютикс, Инк.	Способы и системы кондиционирования дисперсных кристаллических материалов
ITMI20130571A1 (it) *	2013-04-10	2014-10-11	Zambon Spa	Composizione farmaceutica contenente budesonide e formoterolo
US9427376B2 (en) *	2013-10-10	2016-08-30	Chiesi Farmaceutici S.P.A.	Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN115844860A (zh) *	2014-10-08	2023-03-28	萨宝公司	用于吸入使用的粉末形式的药物组合物及试剂盒
GB2545025A (en) *	2015-12-04	2017-06-07	Mexichem Fluor Sa De Cv	Pharmaceutical composition
WO2017093758A1 (en)	2015-12-04	2017-06-08	Mexichem Fluor S.A. De C.V.	Pharmaceutical composition
CN115813935A (zh) *	2021-09-16	2023-03-21	上海上药信谊药厂有限公司	药物组合物、气雾剂及其制备方法和气雾剂产生系统
CN116763797B (zh) *	2022-03-09	2025-09-02	上海医药工业研究院有限公司	一种药物组合微球、其制备方法及其原料组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL95590A (en)	1989-09-08	1996-06-18	Glaxo Group Ltd	Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5874063A (en)	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
ES2172510T3 (es)	1991-12-18	2002-10-01	Astrazeneca Ab	Nueva combinacion de formoterol y budesonida.
US6596260B1 (en)	1993-08-27	2003-07-22	Novartis Corporation	Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5837699A (en)	1994-01-27	1998-11-17	Schering Corporation	Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es)	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
FI972655L (fi)	1994-12-22	1997-06-19	Astra Ab	Aerosolilääkeformuloinnit
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
WO1998034595A1 (de) *	1997-02-05	1998-08-13	Jago Research Ag	Medizinische aerosolformulierungen
AU741783B2 (en) *	1997-03-20	2001-12-06	Merck Sharp & Dohme Corp.	Preparation of powder agglomerates
EP1033991B1 (de) *	1997-10-09	2002-04-17	Schering Corporation	Mometasonfuroat-suspensionen zum zerstäuben
MY133181A (en) *	1998-09-10	2007-10-31	Schering Corp	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) *	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
TWI324934B (en) *	2001-08-28	2010-05-21	Schering Corp	Pharmaceutical compositions for the treatment of asthma

1999
- 1999-03-03 GB GBGB9904919.9A patent/GB9904919D0/en not_active Ceased
2000
- 2000-03-01 DK DK00910739T patent/DK1156790T3/da active
- 2000-03-01 WO PCT/EP2000/001722 patent/WO2000051591A1/en not_active Ceased
- 2000-03-01 AU AU32843/00A patent/AU770739B2/en not_active Expired
- 2000-03-01 IL IL14435100A patent/IL144351A/en not_active IP Right Cessation
- 2000-03-01 RU RU2001126347/63A patent/RU2270670C2/ru active
- 2000-03-01 BR BR0008699-1A patent/BR0008699A/pt not_active Application Discontinuation
- 2000-03-01 AT AT00910739T patent/ATE241970T1/de active
- 2000-03-01 JP JP2000602059A patent/JP2002538110A/ja not_active Withdrawn
- 2000-03-01 CA CA002362499A patent/CA2362499C/en not_active Expired - Lifetime
- 2000-03-01 PL PL349566A patent/PL212355B1/pl unknown
- 2000-03-01 KR KR1020017011162A patent/KR100682418B1/ko not_active Expired - Lifetime
- 2000-03-01 HU HU0200142A patent/HU229073B1/hu unknown
- 2000-03-01 PT PT00910739T patent/PT1156790E/pt unknown
- 2000-03-01 EP EP00910739A patent/EP1156790B1/de not_active Expired - Lifetime
- 2000-03-01 DE DE60003160T patent/DE60003160T2/de not_active Expired - Lifetime
- 2000-03-01 ES ES00910739T patent/ES2200837T3/es not_active Expired - Lifetime
- 2000-03-01 EP EP03003950A patent/EP1325765A1/de not_active Withdrawn
- 2000-03-01 ID IDW00200101780A patent/ID30171A/id unknown
- 2000-03-01 HK HK02103183.9A patent/HK1043048B/en unknown
- 2000-03-01 NZ NZ513742A patent/NZ513742A/en not_active IP Right Cessation
- 2000-03-01 CZ CZ20013168A patent/CZ294089B6/cs not_active IP Right Cessation
- 2000-03-01 SK SK1230-2001A patent/SK286338B6/sk not_active IP Right Cessation
- 2000-03-01 CN CNB008041911A patent/CN1196478C/zh not_active Expired - Lifetime
2001
- 2001-08-06 ZA ZA200106442A patent/ZA200106442B/en unknown
- 2001-08-16 NO NO20013988A patent/NO331428B1/no not_active IP Right Cessation
- 2001-08-30 US US09/942,805 patent/US20020055494A1/en not_active Abandoned
2002
- 2002-10-01 US US10/262,408 patent/US20030050290A1/en not_active Abandoned
2003
- 2003-11-20 US US10/718,316 patent/US7067502B2/en not_active Expired - Lifetime
2004
- 2004-05-20 CL CL200401170A patent/CL2004001170A1/es unknown
2005
- 2005-08-08 US US11/199,291 patent/US7566705B2/en not_active Expired - Fee Related
2009
- 2009-07-27 JP JP2009174025A patent/JP5646828B2/ja not_active Expired - Lifetime
2013
- 2013-01-23 JP JP2013010543A patent/JP5663046B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1341017A (zh)	2002-03-20
BR0008699A (pt)	2001-12-26
HUP0200142A2 (en)	2002-06-29
ATE241970T1 (de)	2003-06-15
SK286338B6 (en)	2008-07-07
RU2270670C2 (ru)	2006-02-27
ZA200106442B (en)	2002-09-05
PT1156790E (pt)	2003-10-31
CL2004001170A1 (es)	2005-03-28
US20030050290A1 (en)	2003-03-13
EP1156790B1 (de)	2003-06-04
US20040105822A1 (en)	2004-06-03
DK1156790T3 (da)	2003-09-29
US7566705B2 (en)	2009-07-28
JP5663046B2 (ja)	2015-02-04
US20020055494A1 (en)	2002-05-09
PL212355B1 (pl)	2012-09-28
AU3284300A (en)	2000-09-21
US20060009437A1 (en)	2006-01-12
CN1196478C (zh)	2005-04-13
CZ20013168A3 (cs)	2001-12-12
CA2362499A1 (en)	2000-09-08
HK1043048A1 (en)	2002-09-06
NO331428B1 (no)	2011-12-27
EP1156790A1 (de)	2001-11-28
GB9904919D0 (en)	1999-04-28
AU770739B2 (en)	2004-03-04
EP1325765A1 (de)	2003-07-09
CA2362499C (en)	2009-01-27
KR20010102473A (ko)	2001-11-15
HK1043048B (en)	2004-01-30
HU229073B1 (en)	2013-07-29
SK12302001A3 (sk)	2001-12-03
NZ513742A (en)	2001-09-28
NO20013988D0 (no)	2001-08-16
JP2010001295A (ja)	2010-01-07
US7067502B2 (en)	2006-06-27
WO2000051591A1 (en)	2000-09-08
DE60003160T2 (de)	2004-05-19
NO20013988L (no)	2001-08-16
CZ294089B6 (cs)	2004-10-13
ID30171A (id)	2001-11-08
JP2013067668A (ja)	2013-04-18
DE60003160D1 (de)	2003-07-10
KR100682418B1 (ko)	2007-02-15
IL144351A0 (en)	2002-05-23
JP2002538110A (ja)	2002-11-12
JP5646828B2 (ja)	2014-12-24
ES2200837T3 (es)	2004-03-16

Legal Events

Date	Code	Title
2006-07-05	FF	Patent granted
2006-08-01	KB	Patent renewed
2010-10-31	KB	Patent renewed
2014-02-27	KB	Patent renewed
2018-02-28	KB	Patent renewed
2020-10-29	EXP	Patent expired

Publication	Publication Date	Title
CA2362499C (en)	2009-01-27	Combinations of formoterol and mometasone furoate for asthma
EP1152753B1 (de)	2004-05-12	Kombinationen von formoterol und fluticasonpropionat für asthma
CA2360248C (en)	2009-01-27	Combinations of formoterol and a tiotropium salt
HK1042429B (en)	2005-04-01	Combinations of formoterol and fluticasone propionate for asthma
MXPA01008879A (en)	2002-05-09	Combinations of formoterol and mometasone furoate for asthma
MXPA01008360A (en)	2002-05-09	Combinations of formoterol and fluticasone propionate for asthma
MXPA01008001A (en)	2002-05-09	Combinations of formoterol and a tiotropium salt